Committee for Proprietary Medicinal Products (CPMP)

@inproceedings{Nahler2009CommitteeFP,
  title={Committee for Proprietary Medicinal Products (CPMP)},
  author={G. Nahler},
  year={2009}
}
Committee of the EC formed by representatives of national registration authorities; members have to assess new applications for biotechnology and other novel medicines as well as to settle disputes between member states when they disagree as to whether a product may be licensed for use in their territory; for “high-technology” products the CPMP is the chosen but not mandatory approval route; → see also multistate procedure, centralised procedure. 
285 Citations
The Regulatory System in Europe with Special Emphasis on Allergen Products
  • 29
Acceptability of Low Levels of Genotoxic Impurities in New Drug Substances
  • 10
Setting Limits for Genotoxic Impurities in Drug Substances
  • 5
New adjuvants: EU regulatory developments
  • 18
Regulatory aspects of specific immunotherapy in Europe
  • 18
[The patents game. Generic and biosimilar drugs].
  • 1
...
1
2
3
4
5
...